Prostate Impendance Test Project (PROSIT)
Prostate Impendance Test Project (PROS.IT) in Prostate Cancer Diagnosis: a Cross-sectional Observational Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tommaso Di Vico, Resident
- Phone Number: 3393642655
- Email: urologiapisa@gmail.com
Study Locations
-
-
Toscana
-
Pisa, Toscana, Italy, 56124
- Recruiting
- AOUP Ospedale cisanello
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- age> 45 years
- up of total PSA values beyond the normal range (> 4 ng / ml)
- presence or absence of suspicious prostate nodule
Exclusion Criteria:
- previous history of cancer
- BMI>30
- patients with previous diagnosis of PIN HG at prostate core biopsy or in active surveillance
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
patients undergoing prostatic biopsy
Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Impedance-based analysis based on phase-sensitive sensors
Time Frame: during rectal examination
|
during rectal examination
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 151/2016
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
NCT04141709RecruitingOligometastatic Disease | Prostatic Cancer, Castration-Resistant
-
NCT03551782Completed
-
NCT02254785UnknownMetastatic Castration-Resistant Prostatic Cancer
-
NCT04833517RecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic Cancer
-
NCT01981707TerminatedCastration-resistant Prostate Cancer
-
NCT04126915Not yet recruitingCastration-Resistant Prostatic Cancer
-
NCT02866916WithdrawnProstatic Cancer, Castration-Resistant
-
NCT02687308CompletedProstatic Cancer | Prostatic Neoplasm
-
NCT03748641Active, not recruiting
-
NCT04404140Terminated